Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
10.3341/kjo.2015.29.4.226
- Author:
Da Ru Chi MOON
1
;
Dong Kyu LEE
;
Soon Hyun KIM
;
Yong Sung YOU
;
Oh Woong KWON
Author Information
1. Retina Center, Nune Eye Hospital, Seoul, Korea. owkwon0301@gmail.com
- Publication Type:Original Article
- Keywords:
Aflibercept;
Anti-vascular endothelial growth factor;
Bevacizumab;
Macular degeneration;
Polypoidal choroidal vasculopathy
- MeSH:
Angiogenesis Inhibitors/administration & dosage;
Bevacizumab/administration & dosage;
Choroid/*blood supply;
Choroid Diseases/complications/diagnosis/*drug therapy;
Dose-Response Relationship, Drug;
Drug Therapy, Combination;
Female;
Follow-Up Studies;
Humans;
Intravitreal Injections;
Male;
Ranibizumab/administration & dosage;
Receptors, Vascular Endothelial Growth Factor/*administration & dosage;
Recombinant Fusion Proteins/*administration & dosage;
Retinal Neovascularization/complications/diagnosis/*drug therapy;
Retrospective Studies;
Tomography, Optical Coherence;
Treatment Outcome;
Vascular Endothelial Growth Factor A/*antagonists & inhibitors;
*Visual Acuity;
Wet Macular Degeneration/diagnosis/*drug therapy/etiology
- From:Korean Journal of Ophthalmology
2015;29(4):226-232
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To report the results of switching treatment to vascular endothelial growth factor (VEGF) Trap-Eye (aflibercept) in neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) refractory to anti-VEGF (ranibizumab and bevacizumab). METHODS: This is a retrospective study involving 32 eyes from 29 patients; 18 were cases of neovascular AMD and 14 were cases of PCV. The best-corrected visual acuity (BCVA) and central macular thickness (CMT) of spectral-domain optical coherence tomography were evaluated. RESULTS: BCVA and CMT improved from 0.58 to 0.55 (p = 0.005) and from 404 to 321 microm (p < 0.001), respectively, after switching to aflibercept. The 14 eyes that received 6 or more aflibercept injections remained stable at 0.81 to 0.81 and 321 to 327 microm (p = 1.0, 0.29), respectively, after 3 aflibercept injections. The 10 eyes that received 3 or more bevacizumab injections after 3 or more aflibercept injections worsened, from 0.44 to 0.47 and from 332 to 346 microm (p = 0.06, 0.05), respectively. The results showed similar improvement of BCVA and CMT in neovascular AMD and PCV. CONCLUSIONS: Aflibercept seems to be effective for improvement and maintenance of BCVA and CMT for neovascular AMD and PCV refractory to anti-VEGF. Switching from aflibercept back to bevacizumab treatment may not be a proper strategy.
